• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Serum 25-Hydroxyvitamin D and Breast Cancer in the Military: A Case-control Study Utilizing Pre-diagnostic Serum.
【24h】

Serum 25-Hydroxyvitamin D and Breast Cancer in the Military: A Case-control Study Utilizing Pre-diagnostic Serum.

机译：血清25-羟基维生素D和军队中的乳腺癌：使用预诊断血清的病例对照研究。

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. The objective of this study was to test whether a relationship exists between prediagnostic serum levels of 25-hydroxyvitamin D (25(OH)D) and subsequent risk of breast cancer in an active-duty U.S. military cohort. Methods. 600 incident cases of female breast cancer were matched to 600 female controls as part of a nested case control study. Conditional logistic regression was used to assess the relationship between serum 25(OH)D concentration and breast cancer risk, while controlling for race and age Findings. The quintile cutpoints were < 15, 15-21.7, 27.4-35.1, and > 35.1 ng/ml. There was a trend toward an inverse association between serum 25(OH)D and odds of breast cancer. In pairs in which serum was collected less than 90 days before diagnosis of the case, women in the highest quintile of serum 25(OH)D had 70% lower estimated risk of breast cancer (odds ratio 0.30, 95% confidence interval 0.12-0.74, p < 0.01 for contrast) compared to those in the lowest. Interpretation. The favorable association of serum 25(OH)D with risk of breast cancer suggest that the influence of serum 25(OH)D in risk of breast cancer in adult women was strongest during the final few doublings of the tumor mass preceding diagnosis in this population. Further epidemiological research, including cohort studies, of the relationship between serum 25(OH)D status and breast cancer risk and its timing should be undertaken to confirm this association.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号